Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug to see if it is safe and effective for treating patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am allergic to Dox, hyaluronic acid, or certain bacterial proteins.I do not have any uncontrolled health conditions.I have been diagnosed with advanced soft tissue sarcoma or another type of solid tumor.I have received Trastuzumab or Trastuzumab emtansine within the last 7 months.I have not had any major surgeries recently.My cancer type responds to a specific chemotherapy drug.I am fully active or can carry out light work.My blood, liver, kidney, and clotting tests are within normal ranges.I have stable brain metastases after treatment.I have previously received a specific dose of Doxorubicin or Epirubicin.I have a tumor that can be injected.I am not currently on chemotherapy, immunotherapy, or anticancer therapy.I have not had a blood transfusion in the last 14 days.I am currently undergoing or have completed radiotherapy.I have severe heart issues, including heart failure or irregular heartbeat.
- Group 1: Dose Escalation Cohort (20 mL SQL70)
- Group 2: Phase 2a Expansion Group 3a (Head and Neck)
- Group 3: Cohort A
- Group 4: Dose Escalation Cohort (10 mL SQL70)
- Group 5: Phase 2a Expansion Group 1 (Extremity STS)
- Group 6: Phase 2a Expansion Group 2 (Unresectable STS)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please tell me how many different places are in charge of this trial?
"There are 11 trial locations for this study, which are currently enrolling patients. Some of these sites include Sarcoma Oncology Center in Santa Monica, California, Mary Crowley Cancer Research in Dallas, Texas, and Oregon Health & Science University in Portland, Oregon."
Why was this clinical trial designed, and what are its key goals?
"The sponsor of this clinical trial, Shasqi, Inc., reports that the primary objective is Phase 2a Expansion Groups. This will be measured over a 12-week period from the start of treatment. Additionally, there are secondary objectives including but not limited to: measuring plasma concentration and PK parameters for SQP33 protodrug and active Dox following SQ3370 treatment (Phase 2a: Pharmacokinetics), determining the time between enrollment and death from any cause (Phase 2a: Overall Survival), and finally, to determine Maximum Plasma concentration (Cmax) for SQP33 protodrug and active Dox following SQ33"
How many people are receiving care through this research project?
"One hundred and forty-five patients are required to carry out this clinical trial according to the current inclusion criteria. The sponsor, Shasqi, Inc., will manage the study from centres in Sarcoma Oncology Center (Santa Monica, California) and Mary Crowley Cancer Research (Dallas, Texas)."
Are there still room for participants in this research?
"Yes, this trial is still open and recruiting patients according to the latest update on clinicaltrials.gov from September 16th, 2022. The original posting was on August 1st, 2020."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger